Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Bayer Pharma Aktiengesellschaft has 7 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 7 examiners and 7 art units, indicating a fully distributed examination structure in the available data, with no shared examiner or art-unit assignment identified.
MCKOY, QUINCY ANDRE is the busiest examiner, with 1 pending matter. That limited individual workload means no single examiner dominates the docket, so counsel should prepare for varied examination positions across the matters.
The breadth of examiner and art-unit coverage makes docket segmentation important. Responses should be coordinated for portfolio consistency while preserving matter-specific analysis of the applicable technical and claim issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Double-patenting only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| No statute on record | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| LOCKARD, JON MCCLELLAND | 1 | 74.4% | +27.4% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336769 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | LOCKARD, JON MCCLELLAND | 42d overdue |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | SAMALA, JAGADISHWAR RAO | 31d overdue |
| 18964918 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | MCKOY, QUINCY ANDRE | — |
| 18779518 | TREATMENT OF CARDIOPULMONARY DISORDERS | BORI, IBRAHIM D | — |
| 18725470 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | GEMBEH, SHIRLEY V | — |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | — |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1629 | 1 |
| 1615 | 1 |
| 1647 | 1 |
| 1646 | 1 |
| 1621 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18964918 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | MCKOY, QUINCY ANDRE | 1626 | DP | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18779518 | TREATMENT OF CARDIOPULMONARY DISORDERS | BORI, IBRAHIM D | 1629 | Other | Final Rejection | — | Pending | Jul 22, 2024 |
| 18725470 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | GEMBEH, SHIRLEY V | 1615 | Other | Final Rejection | — | Pending | Jun 28, 2024 |
| 18336769 | SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES | LOCKARD, JON MCCLELLAND | 1647 | DP | Final Rejection | 42d overdue | Pending | Jun 16, 2023 |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | 1646 | DP | Non-Final OA | — | Pending | Feb 27, 2023 |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | 1621 | §103 | Final Rejection | — | Pending | Nov 17, 2022 |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | SAMALA, JAGADISHWAR RAO | 1618 | §112DP | Final Rejection | 31d overdue | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBayer Pharma Aktiengesellschaft has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Quincy Andre Mckoy has the most, with 1 of Bayer Pharma Aktiengesellschaft's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
